Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically ...

Altimmune, Inc. ALT posted a loss for the second quarter on Tuesday. The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's ...

Altimmune (NASDAQ:ALT) shares rose on Tuesday after the company reported promising Q2 results banking on its experimental candidate, pemvidutide. Pemvidutide is in development for the treatment of ...

Altimmune ( ($ALT) ) has released its Q2 earnings. Here is a breakdown of the information Altimmune presented to its investors. Altimmune, Inc. is ...

NEW YORK - August 15, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit.

Altimmune, Inc. ( NASDAQ: ALT) Q2 2025 Earnings Call August 12, 2025 8:30 AM ET Gregory L. Weaver - Chief Financial Officer Scott Harris - Corporate Participant Vipin K. Garg - President, CEO & ...

Dr. Scott Harris, Chief Medical Officer of Altimmune, emphasized that “Based on the results generated in the IMPACT trial, pemvidutide demonstrated significant MASH resolution and encouraging ...

News provided by Altimmune, Inc Jun 26, 2025, 7:00 AM ET First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with ...

GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for ...

Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent ...

--Altimmune, Inc., a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. "2024 ...